



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Irisquinone

Cat. No.:	HY-N7147
CAS No.:	56495-82-0
Molecular Formula:	C <sub>24</sub> H <sub>38</sub> O <sub>3</sub>
Molecular Weight:	374.56
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Irisquinone, a natural product, is an anticancer agent. Irisquinone is also a radiation sensitizer for cancer. Irisquinone reduces GSH level and inhibits the repair of DNA singular strand breaks <sup>[1][2][3]</sup> .
In Vitro	Irisquinone (0-128 nM, 12-48 h) induces cell death of C6 rat glioma cells <sup>[2]</sup> . Irisquinone (4.2 nM, 48 h) increases the radiosensitivity of C6 rat glioma cells <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[2]</sup>
	Cell Line: C6 rat glioma cells
	Concentration: 0, 4, 8, 16, 32, 64, 128 nM
	Incubation Time: 12, 24, 48 h
	Result: Time-dependently and dose-dependently inhibited cell viability.
In Vivo	Irisquinone (12.5 mg/kg, perfused daily) makes the rabbit VX2 lung transplant tumor wall thinner and the necrotic area larger in the irisquinone + radiotherapy group <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
	Animal Model: Rabbit bearing VX2 lung transplant tumor <sup>[1]</sup>
	Dosage: 12.5 mg/kg
	Administration: Perfused daily, starting from 3 days before irradiation to the end of irradiation.
	Result: Displayed no significant difference of tumor growth between the radio therapy and Irisquinone + radiotherapy groups. Showed thinner tumor wall and the larger necrotic area in the Irisquinone + radiotherapy group.

### REFERENCES

---

[1]. Xu H, et al. Dynamic observation of the radiosensitive effect of irisquinone on rabbit VX2 lung transplant tumors by using fluorine-18-deoxyglucose positron emission tomography/computed tomography. Nucl Med Commun. 2013 Mar;34(3):220-8.

[2]. Wang H, et al. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1 $\alpha$  evaluated by 18F-FDG and 18F-FMISO PET/CT. Nucl Med Commun. 2016 Jul;37(7):705-14.

[3]. Liang, L., et al. The effect of Irisquinone on the glutathione system and MRP expression of cisplatin-resistant human lung adenocarcinoma cell line (A DDP549). Chin J Cancer Res 13, 171–175 (2001).

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA